28,046,696 Options of Radiopharm Theranostics Limited are subject to a Lock-Up Agreement Ending on 25-NOV-2023. These Options will be under lockup for 737 days starting from 18-NOV-2021 to 25-NOV-2023.

Details:
In accordance with the requirements of the ASX Listing Rules, the Existing Shareholders shall be restricted from dealing in the Shares held by them until the date which is either 12 months from the date of issue of their relevant security or 24 months from the date of the Company's listing on ASX.

In total, 136,666,574 of the 253,333,557 (53.95%) Shares on issue on Completion of the Offer are anticipated to be subject to ASX mandatory escrow arrangements, the details of which are as follows, 100,000,000 Shares held by Existing Shareholders (which will represent 39.47%of the Shares on issue following Completion of the Offer) will be subject to ASX mandatory escrow for 24 months from Completion, 25,555,555 Shares held by certain Licensors on Completion of the Offer (which will represent 10.09% of the Shares on issue following Completion of the Offer) will be subject to ASX mandatory escrow for 12 months from the date of issuance of those Shares; and 11,111,019 Shares issued to Convertible Note Holders upon conversion of the Convertible Notes (which will represent 4.38% of the Shares on issue following Completion of the Offer) will be subject to ASX mandatory escrow for 12 months from the date the Convertible Notes were issued.

All Shares and Options held by Directors are subject to mandatory escrow for 24 months from the date of the Company's listing on ASX.